FindTrial
Sign In

THE USE OF CASPOFUNGIN(CANCIDAS) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCES AND CONCOMITANT CANDIDEMIA

THE USE OF CASPOFUNGIN(CANCIDAS) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCES AND CONCOMITANT CANDIDEMIA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004266-32-IT
Enrollment
Unknown
Registered
2007-08-08
Start date
2006-06-12
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CANDIDEMIA IN HEMATOLOGICAL MALIGNANCIES MedDRA version: 6.1 Level: PT Classification code 10042938

Interventions

Trade Name: CANCIDAS*EV FL 50MG 10ML Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Caspofungin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026